# Completion of ACTIV-2 Study

> **NIH NIH N01** · PPD DEVELOPMENT LP · 2022 · $82,531,927

## Abstract

NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support,
NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for
Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.

## Key facts

- **NIH application ID:** 10710623
- **Project number:** 75N93021D00035-0-759302200002-1
- **Recipient organization:** PPD DEVELOPMENT LP
- **Principal Investigator:** ANGEE GREER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $82,531,927
- **Award type:** —
- **Project period:** 2022-11-06 → 2024-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10710623

## Citation

> US National Institutes of Health, RePORTER application 10710623, Completion of ACTIV-2 Study (75N93021D00035-0-759302200002-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10710623. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*